Pevifoscorvir sodium clinical trials
Also written ALG-000184.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses pevifoscorvir sodium is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Aligos Therapeutics (5)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test pevifoscorvir sodium.
Studies
Open first, then newest update. How each study uses pevifoscorvir sodium is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)Active, not recruitingPhase 2Aligos TherapeuticsNCT06963710Written as ALG-000184
- Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal FunctionCompletedPhase 1Aligos TherapeuticsNCT07342881Written as Pevifoscorvir Sodium (ALG-000184)
- Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic FunctionCompletedPhase 1Aligos TherapeuticsNCT07342868Written as Pevifoscorvir Sodium (ALG-000184)
- A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB SubjectsCompletedPhase 1Aligos TherapeuticsNCT04536337Written as ALG-000184
- A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy VolunteersActive, not recruitingPhase 1Aligos TherapeuticsNCT06672900Written as ALG-000184
Codes
What other systems call pevifoscorvir sodium · ClinicalTrials.gg INT017717
- UNII (FDA) QUF596Z92TPEVIFOSCORVIR SODIUMOne source FDA
- NCI Thesaurus C226378Pevifoscorvir SodiumOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QUF596Z92T | PEVIFOSCORVIR SODIUM | One source FDA |
| NCI Thesaurus | C226378 | Pevifoscorvir Sodium | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.